Welcome to the UPF Digital Repository

Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics

Show simple item record

dc.contributor.author Tierling, Sascha
dc.contributor.author Jürgens-Wemheuer, Wiebke M.
dc.contributor.author Leismann, Alea
dc.contributor.author Becker-Kettern, Julia
dc.contributor.author Scherer, Michael
dc.contributor.author Wrede, Arne
dc.contributor.author Breuskin, David
dc.contributor.author Urbschat, Steffi
dc.contributor.author Sippi, Christoph
dc.contributor.author Oertel, Joachim
dc.contributor.author Schulz-Schaeffer, Walter J.
dc.contributor.author Walter, Jörn
dc.date.accessioned 2022-04-05T10:07:26Z
dc.date.available 2022-04-05T10:07:26Z
dc.date.issued 2022
dc.identifier.citation Tierling S, Jürgens-Wemheuer WM, Leismann A, Becker-Kettern J, Scherer M, Wrede A et al. Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. Clin Epigenetics. 2022 Feb 18;14(1):26. DOI: 10.1186/s13148-022-01244-4.
dc.identifier.issn 1868-7075
dc.identifier.uri http://hdl.handle.net/10230/52828
dc.description.abstract Background: Promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is an acknowledged predictive epigenetic marker in glioblastoma multiforme and anaplastic astrocytoma. Patients with methylated CpGs in the MGMT promoter benefit from treatment with alkylating agents, such as temozolomide, and show an improved overall survival and progression-free interval. A precise determination of MGMT promoter methylation is of importance for diagnostic decisions. We experienced that different methods show partially divergent results in a daily routine. For an integrated neuropathological diagnosis of malignant gliomas, we therefore currently apply a combination of methylation-specific PCR assays and pyrosequencing. Results: To better rationalize the variation across assays, we compared these standard techniques and assays to deep bisulfite sequencing results in a cohort of 80 malignant astrocytomas. Our deep analysis covers 49 CpG sites of the expanded MGMT promoter, including exon 1, parts of intron 1 and a region upstream of the transcription start site (TSS). We observed that deep sequencing data are in general in agreement with CpG-specific pyrosequencing, while the most widely used MSP assays published by Esteller et al. (N Engl J Med 343(19):1350-1354, 2000. https://doi.org/10.1056/NEJM200011093431901 ) and Felsberg et al. (Clin Cancer Res 15(21):6683-6693, 2009. https://doi.org/10.1158/1078-0432.CCR-08-2801 ) resulted in partially discordant results in 22 tumors (27.5%). Local deep bisulfite sequencing (LDBS) revealed that CpGs located in exon 1 are suited best to discriminate methylated from unmethylated samples. Based on LDBS data, we propose an optimized MSP primer pair with 83% and 85% concordance to pyrosequencing and LDBS data. A hitherto neglected region upstream of the TSS, with an overall higher methylation compared to exon 1 and intron 1 of MGMT, is also able to discriminate the methylation status. Conclusion: Our integrated analysis allows to evaluate and redefine co-methylation domains within the MGMT promoter and to rationalize the practical impact on assays used in daily routine diagnostics.
dc.description.sponsorship Funding: Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Epigenome Programme (DEEP) of the Federal Ministry of Education and Research in Germany (BMBF) (01KU1216F). MS is supported by the BMBF project de.NBI-epi (031L0101D) and the EU H2020 project SYSCID (733100)
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher BioMed Central
dc.rights © Sascha Tierling et al. 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.subject.other Glioblastoma multiforme
dc.subject.other ADN -- Metilació
dc.subject.other Diagnòstic
dc.title Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1186/s13148-022-01244-4
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/733100
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking